SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-036450
Filing Date
2020-08-05
Accepted
2020-08-05 08:01:21
Documents
58
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q - JUNE 30, 2020 alna-10q_20200630.htm 10-Q 2183438
2 EX-31.1 alna-ex311_6.htm EX-31.1 16662
3 EX-31.2 alna-ex312_8.htm EX-31.2 16701
4 EX-32.1 alna-ex321_7.htm EX-32.1 10195
  Complete submission text file 0001564590-20-036450.txt   5576133

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT alna-20200630.xml EX-101.INS 890756
6 XBRL TAXONOMY EXTENSION SCHEMA alna-20200630.xsd EX-101.SCH 37272
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE alna-20200630_cal.xml EX-101.CAL 33991
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE alna-20200630_def.xml EX-101.DEF 133904
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20200630_lab.xml EX-101.LAB 318522
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20200630_pre.xml EX-101.PRE 248110
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38268 | Film No.: 201075694
SIC: 2836 Biological Products, (No Diagnostic Substances)